ADBiotech Statistics

Total Valuation

ADBiotech has a market cap or net worth of KRW 46.18 billion. The enterprise value is 53.29 billion.

Market Cap	46.18B
Enterprise Value	53.29B

Important Dates

The next estimated earnings date is Monday, August 11, 2025.

Earnings Date	Aug 11, 2025
Ex-Dividend Date	n/a

Share Statistics

ADBiotech has 11.36 million shares outstanding. The number of shares has increased by 1.35% in one year.

Current Share Class	11.36M
Shares Outstanding	11.36M
Shares Change (YoY)	+1.35%
Shares Change (QoQ)	+5.40%
Owned by Insiders (%)	34.83%
Owned by Institutions (%)	4.29%
Float	9.36M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	3.96
PB Ratio	7.73
P/TBV Ratio	7.81
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	-13.08
EV / Sales	4.57
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-12.42

Financial Position

The company has a current ratio of 0.73, with a Debt / Equity ratio of 2.10.

Current Ratio	0.73
Quick Ratio	0.49
Debt / Equity	2.10
Debt / EBITDA	n/a
Debt / FCF	-2.92
Interest Coverage	-4.47

Financial Efficiency

Return on equity (ROE) is -73.36% and return on invested capital (ROIC) is -12.04%.

Return on Equity (ROE)	-73.36%
Return on Assets (ROA)	-9.71%
Return on Invested Capital (ROIC)	-12.04%
Return on Capital Employed (ROCE)	-35.83%
Revenue Per Employee	197.63M
Profits Per Employee	-69.07M
Employee Count	59
Asset Turnover	0.48
Inventory Turnover	2.78

Taxes

Income Tax	-25.65M
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has increased by +4.55% in the last 52 weeks. The beta is 0.99, so ADBiotech's price volatility has been similar to the market average.

Beta (5Y)	0.99
52-Week Price Change	+4.55%
50-Day Moving Average	2,355.22
200-Day Moving Average	2,497.88
Relative Strength Index (RSI)	57.37
Average Volume (20 Days)	1,392,822

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, ADBiotech had revenue of KRW 11.66 billion and -4.07 billion in losses. Loss per share was -440.11.

Revenue	11.66B
Gross Profit	4.42B
Operating Income	-3.74B
Pretax Income	-5.13B
Net Income	-4.07B
EBITDA	-2.72B
EBIT	-3.74B
Loss Per Share	-440.11

Full Income Statement

Balance Sheet

The company has 3.90 billion in cash and 12.52 billion in debt, giving a net cash position of -8.62 billion or -758.80 per share.

Cash & Cash Equivalents	3.90B
Total Debt	12.52B
Net Cash	-8.62B
Net Cash Per Share	-758.80
Equity (Book Value)	5.98B
Book Value Per Share	658.98
Working Capital	-4.01B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -4.09 billion and capital expenditures -201.74 million, giving a free cash flow of -4.29 billion.

Operating Cash Flow	-4.09B
Capital Expenditures	-201.74M
Free Cash Flow	-4.29B
FCF Per Share	-377.65

Full Cash Flow Statement

Margins

Gross margin is 37.89%, with operating and profit margins of -32.12% and -34.95%.

Gross Margin	37.89%
Operating Margin	-32.12%
Pretax Margin	-43.97%
Profit Margin	-34.95%
EBITDA Margin	-23.35%
EBIT Margin	-32.12%
FCF Margin	n/a

Dividends & Yields

ADBiotech does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-1.35%
Shareholder Yield	n/a
Earnings Yield	-8.82%
FCF Yield	-9.29%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

The last stock split was on May 26, 2021. It was a forward split with a ratio of 3.

Last Split Date	May 26, 2021
Split Type	Forward
Split Ratio	3

Scores

ADBiotech has an Altman Z-Score of -0.8 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-0.8
Piotroski F-Score	2